Japanese retrospective cohort systemic sclerosis study shows adjunctive tofacitinib improved ower esophageal sphincter pressures (LESP). 50 SSc pts w/ esophageal Sxs Rx w/ Tofa or PBO x 24 wks. Tofa assoc w/ signif LESP increases & lower mRSS & IL-6 levels https://t.co/NNREBddiOi https://t.co/acVOfoorRP

Women's Health and Reproductive Issues: APLAR 2026 https://t.co/E3IjKP91qL https://t.co/imOGOjce83

Autologous HCT in Severe Systemic Sclerosis An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation, adding important evidence on sustained positive clinical outcomes and long-term safety in patients treated for early https://t.co/2YhuAwMsXe

Three Tips to Stay on Muscarinic Agonists in Sjögren's Disease Resolution of dryness remains a key unmet need for patients with Sjögren disease (SjD), as highlighted by the Sjögren SIG session “How to treat SjD” on the final day of APLAR 2026. https://t.co/WrG8UF8Sne https://t.co/QMmZfUYWLq

Big meeting. Plenty to talk about. Join RheumNow’s daily ACR 2026 recaps for standout data, thoughtful debate and clinical takeaways. Sunday, Nov. 8–Wednesday, Nov. 11 6 PM ET / 5 PM CT / 3 PM PT Watch LIVE on X, YouTube, Facebook or LinkedIn. https://t.co/SX6sSX9Tbe

Medscape overview of Fibromyalgia Therapies. Only four FDA approved FM drugs in the USA - pregabalin (2007), duloxetine (2008), milnacipran (2009) & sublingual cyclobenzaprine (2025) but none approved by the EMA in Europe. https://t.co/QHFSmcozT0 https://t.co/oiVjf4GZGX

APLAR 2026: Who can reduce DMARDs in RA? https://t.co/npUC1hjlYT https://t.co/ExnNEe9gZQ

APLAR 2026: CAR T in Rheumatology: Promise or Peril? https://t.co/nw1iu7eCpn https://t.co/61Z2mn3vln

The Concern about Seronegative RA A current review of seronegative RA (SNRA) by D’Onofrio, et al in npj Autoimmunity shows the diverse fate of seronegative RA - which can resolve, persist or become refractory. Clearly dedicated trials of SNRA are needed to better predict. https://t.co/98VDKucMgX

Pregnancy in Lupus Nephritis and RA: Managing risks and treating to target A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern https://t.co/cTVvyXBbug

APLAR 2026: The Rheumatologist and AI https://t.co/g81loiW0pI https://t.co/udiw3eoNJr

FDA Approves Tildrakizumab for Psoriatic Arthritis Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis. https://t.co/9vJoJ35iso https://t.co/4ePITTmPl8

Intra-Articular Injections for Knee OA: Options, Evidence, and no Clear Winner At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im. The products fall into three tiers: symptom-modifying, biologic/regenerative https://t.co/jWuinfM2W6

DERM on RheumNow (October 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – Features Dr. Jack Cush, Editor at RheumNow. https://t.co/AfVKHsj47T https://t.co/LlWIKdyFJ1

Exagen studies 192 established RA pts (383 controls) for Abs: CCP2, RF IgA, RF IgM, PAD4 (IgA, IgG). RA signif assoc w/ CCP2+ (OR 110), RF (>7), PAD4 (3.5-5.9). In CCP neg - only PAD4 IgG (2.87) & RF (2.2) assoc w/ RA, w/ only small Dx gain (ΔAUC 0.02–0.04). https://t.co/isf7aMf24O